In:
BMC Cancer, Springer Science and Business Media LLC, Vol. 23, No. 1 ( 2023-07-31)
Abstract:
Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/ levo -leucovorin ( Levo -LV) was approved for unresectable pancreatic cancer (UR-PC) in March 2020 in Japan. Levo -LV is administered by intravenous infusion over 120 min following 90 min intravenous infusion of nal-IRI (conventional method), causing a significant burden on both patients and the outpatient chemotherapy room owing to the prolonged administration time. Thus, from July 2021, we introduced the simultaneous intravenous administration of nal-IRI and Levo -LV (parallel method) with the approval of the institutional regimen committee. Methods We retrospectively reviewed the data of 69 patients with UR-PC who received nal-IRI plus 5-FU/ Levo -LV at our hospital between June 2020 and October 2021. We examined the safety of the parallel method and compared the treatment outcomes and administration times between the two methods. Results The median age was 66 years (54%, male). Disease statuses were locally advanced, metastatic, and postoperative recurrence after pancreatectomy in 7, 50, and 12 patients, respectively. Nal-IRI plus 5-FU/ Levo -LV treatment was second and third-line or later in 35 and 34 patients, respectively. No intravenous line problems were observed during the parallel administration of nal-IRI and Levo -LV. Although there were no significant differences in response rates and adverse events between the two methods, the administration time was significantly shorter in the parallel method than in the conventional method. Conclusion The parallel administration of nal-IRI and Levo -LV is clinically safe and not inferior in efficacy. Moreover, parallel administration may offer convenience to patients and healthcare workers by reducing administration time.
Type of Medium:
Online Resource
ISSN:
1471-2407
DOI:
10.1186/s12885-023-11205-6
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2023
detail.hit.zdb_id:
2041352-X
